Ameliorating lymphocyte depletion and functional impairment following lung SBRT

Information

  • Research Project
  • 10232307
  • ApplicationId
    10232307
  • Core Project Number
    R01CA234281
  • Full Project Number
    5R01CA234281-03
  • Serial Number
    234281
  • FOA Number
    PAR-18-011
  • Sub Project Id
  • Project Start Date
    9/1/2019 - 6 years ago
  • Project End Date
    8/31/2022 - 3 years ago
  • Program Officer Name
    VIKRAM, BHADRASAIN
  • Budget Start Date
    9/1/2021 - 4 years ago
  • Budget End Date
    8/31/2022 - 3 years ago
  • Fiscal Year
    2021
  • Support Year
    03
  • Suffix
  • Award Notice Date
    8/31/2021 - 4 years ago
Organizations

Ameliorating lymphocyte depletion and functional impairment following lung SBRT

Abstract Objectives: To evaluate the efficacy of minimizing Stereotactic Body Radiation Therapy (SBRT) effects on lymphocytes and improving overall survival and immune function by selectively reducing dose to blood rich organs, and increasing the dose confomality in the thorax. Method: This will be achieved in two steps: (A) Determine lymphocyte depletion, phenotype and function of lymphocytes in optimized versus un-optimized plans in total of 50 patients under a randomized pilot study. We will evaluate peripheral blood mononuclear cells collected at baseline and at end of treatment, 4, and 24 weeks after lung SBRT on the clinical trial and compare the data for the two arms. (B) Improve the existing simulation algorithm to predict the total lymphocyte loss for a given Radiation Therapy (RT) beam plan using the clinical trial data. This model will take into account patient specific (i) total blood volume (ii) initial lymphocyte count (iii) tumor volume (iv) the organs from the Thorax CT data set (v) time dependent dose map through each organ for a given delivery system, and plan, and convolve these with general information from published literature such as (i) varying blood output to organs (ii) blood velocity for all organs (iii) Random mixing of blood after each trip through the exposed dose area, with the remaining blood volume of the body.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R01
  • Administering IC
    CA
  • Application Type
    5
  • Direct Cost Amount
    140250
  • Indirect Cost Amount
    36465
  • Total Cost
    176715
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    395
  • Ed Inst. Type
    SCHOOLS OF MEDICINE
  • Funding ICs
    NCI:176715\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    UNIVERSITY OF VIRGINIA
  • Organization Department
    RADIATION-DIAGNOSTIC/ONCOLOGY
  • Organization DUNS
    065391526
  • Organization City
    CHARLOTTESVILLE
  • Organization State
    VA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    229044195
  • Organization District
    UNITED STATES